High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

NCT05038228 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Apixaban
DRUG: Rivaroxaban
DRUG: Dabigatran
DRUG: Vitamin K antagonist (VKA)

Sponsor

Pfizer